256 related articles for article (PubMed ID: 34157136)
41. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia.
Cho JH; Kim GY; Pan CJ; Anduaga J; Choi EJ; Mansfield BC; Chou JY
PLoS Genet; 2017 May; 13(5):e1006819. PubMed ID: 28558013
[TBL] [Abstract][Full Text] [Related]
42. Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.
Rajas F; Clar J; Gautier-Stein A; Mithieux G
J Inherit Metab Dis; 2015 May; 38(3):521-7. PubMed ID: 25164786
[TBL] [Abstract][Full Text] [Related]
43. Predominance of the c.648G > T G6PC gene mutation and late complications in Korean patients with glycogen storage disease type Ia.
Kim YM; Choi JH; Lee BH; Kim GH; Kim KM; Yoo HW
Orphanet J Rare Dis; 2020 Feb; 15(1):45. PubMed ID: 32046761
[TBL] [Abstract][Full Text] [Related]
44. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
[TBL] [Abstract][Full Text] [Related]
45. Challenges of Gene Therapy for the Treatment of Glycogen Storage Diseases Type I and Type III.
Jauze L; Monteillet L; Mithieux G; Rajas F; Ronzitti G
Hum Gene Ther; 2019 Oct; 30(10):1263-1273. PubMed ID: 31319709
[TBL] [Abstract][Full Text] [Related]
46. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
[TBL] [Abstract][Full Text] [Related]
47. Misdiagnosis as steatohepatitis in a family with mild glycogen storage disease type 1a.
Shieh JJ; Lu YH; Huang SW; Huang YH; Sun CH; Chiou HJ; Liu C; Lo MY; Lin CY; Niu DM
Gene; 2012 Nov; 509(1):154-7. PubMed ID: 22909800
[TBL] [Abstract][Full Text] [Related]
48. Deletion of the gene encoding the ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein (UGRP)/glucose-6-phosphatase catalytic subunit-beta results in lowered plasma cholesterol and elevated glucagon.
Wang Y; Oeser JK; Yang C; Sarkar S; Hackl SI; Hasty AH; McGuinness OP; Paradee W; Hutton JC; Powell DR; O'Brien RM
J Biol Chem; 2006 Dec; 281(52):39982-9. PubMed ID: 17023421
[TBL] [Abstract][Full Text] [Related]
49. G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a.
Roseman DS; Khan T; Rajas F; Jun LS; Asrani KH; Isaacs C; Farelli JD; Subramanian RR
Mol Ther; 2018 Mar; 26(3):814-821. PubMed ID: 29428299
[TBL] [Abstract][Full Text] [Related]
50. Canine model and genomic structural organization of glycogen storage disease type Ia (GSD Ia).
Kishnani PS; Faulkner E; VanCamp S; Jackson M; Brown T; Boney A; Koeberl D; Chen YT
Vet Pathol; 2001 Jan; 38(1):83-91. PubMed ID: 11199168
[TBL] [Abstract][Full Text] [Related]
51. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
[TBL] [Abstract][Full Text] [Related]
52. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
[TBL] [Abstract][Full Text] [Related]
54. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
[TBL] [Abstract][Full Text] [Related]
55. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
[TBL] [Abstract][Full Text] [Related]
56. The role of kidney in the inter-organ coordination of endogenous glucose production during fasting.
Kaneko K; Soty M; Zitoun C; Duchampt A; Silva M; Philippe E; Gautier-Stein A; Rajas F; Mithieux G
Mol Metab; 2018 Oct; 16():203-212. PubMed ID: 29960865
[TBL] [Abstract][Full Text] [Related]
57. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
58. Off- and on-target effects of genome editing in mouse embryos.
Ayabe S; Nakashima K; Yoshiki A
J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
[TBL] [Abstract][Full Text] [Related]
59. Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Waskowicz LR; Zhou J; Landau DJ; Brooks ED; Lim A; Yavarow ZA; Kudo T; Zhang H; Wu Y; Grant S; Young SP; Huat BB; Yen PM; Koeberl DD
Hum Mol Genet; 2019 Jan; 28(1):143-154. PubMed ID: 30256948
[TBL] [Abstract][Full Text] [Related]
60. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
Liu W; Yang C; Liu Y; Jiang G
Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
